Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
04:00pm, Thursday, 31'st Jul 2025
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus
Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva receives $10 million milestone payment from CTTQ
04:00pm, Monday, 07'th Jul 2025
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 03'rd Jun 2025
Inventiva (IVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
04:00pm, Tuesday, 27'th May 2025
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva reports 2025 First Quarter Financial Information¹
02:30am, Friday, 23'rd May 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025
02:00am, Friday, 23'rd May 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
02:30am, Monday, 05'th May 2025
Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company fo
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
04:00pm, Wednesday, 30'th Apr 2025
Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
04:00pm, Tuesday, 15'th Apr 2025
Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
10:50am, Thursday, 27'th Mar 2025
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentifie
Inventiva reports its 2024 full year results and provides a business update
04:00pm, Wednesday, 26'th Mar 2025
Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev
